CORE LAB TAVI II

Brief summary:

The study is designed to evaluate the safety and effectiveness of the

Transcatheter Aortic Valve and Recapturable Delivery System (product

of Shanghai MicroPort CardioFlow Medtech Co., Ltd.)

It is a prospective, multicenter, single arm, objective performance

criteria controlled clinical investigation

Primary endpoint:

Cumulative all cause mortality of 12 months

CERC Services:

Core Lab activities

Countries:

China

 Number of patient:

144

Center number:

18